G-protein-coupled receptors (GPCRs) in general, the roles of extracellular residues are not well-defined compared to residues in transmembrane helices (TMs). Nevertheless, extracellular residues are important for various functions in both peptideGPCRs and amine-GPCRs. In this study, the V 1a vasopressin receptor was used to systematically investigate the role of extracellular charged residues which are highly conserved throughout a sub-family of peptideGPCRs, using a combination of mutagenesis and molecular modelling. Of the thirteen conserved charged residues identified in the extracellular loops (ECLs) 
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G-protein-coupled receptors (GPCRs) in general, the roles of extracellular residues are not well-defined compared to residues in transmembrane helices (TMs). Nevertheless, extracellular residues are important for various functions in both peptideGPCRs and amine-GPCRs. In this study, the V 1a vasopressin receptor was used to systematically investigate the role of extracellular charged residues which are highly conserved throughout a sub-family of peptideGPCRs, using a combination of mutagenesis and molecular modelling. Of the thirteen conserved charged residues identified in the extracellular loops (ECLs) G-protein-coupled receptors (GPCRs) 1 exhibit a common tertiary structure comprising seven transmembrane helices (TMs) linked by extracellular loops (ECLs) and intracellular loops. The atomic detail of this general GPCR fold has been elucidated for bovine rhodopsin (bRho) using X-ray crystallography (1) . This confirmed that the chromophore 11-cis-retinal is covalently linked to Lys 296 (7.43) in transmembrane helix VII (TMVII) via a protonated Schiff-base and projects into a binding pocket formed within the TM bundle where it interacts with amino acid side-chains and water molecules (1, 2) . Likewise, the binding pocket for small biogenic amine neurotransmitters such as acetylcholine and norepinephrine is buried deep within the TM bundle (3) . Nevertheless, it is known from the bRho X-ray structure that the extracellular domains possess defined structure and are orientated to interact with each other and with the TM helices. Indeed ECL2 of bRho forms ahairpin which plunges down into the helical bundle to form a plug over the chromophore. Furthermore, the orientation of ECL2 in the majority of GPCRs is restrained by a conserved disulfide bond between ECL2 and the top of TMIII (1, 2) .
The neurohypophysial peptide hormones vasopressin (AVP) and oxytocin (OT) generate a wide range of physiological effects, including vasopressor, antidiuretic and uterotonic actions (4, 5) . The effects of AVP/OT are mediated by a family of receptors (V 1a R, V 1b R, V 2 R and OTR) which together with the vasotocin receptor (VTR), mesotocin receptor and isotocin receptor from lower vertebrates, constitute a sub-family of the rhodopsin/β-adrenergic receptor class of GPCRs (Family A). The V 1a R, V 1b R and OTR couple to phospholipase C thereby generating inositol 1,4,5 trisphosphate and diacylglycerol as second messengers, whereas the V 2 R stimulates adenylyl cyclase. The V 1a R is widely distributed and mediates nearly all of the actions of AVP with the exceptions of antidiuresis (V 2 R) and ACTH secretion (V 1b R). Activation of the OTR stimulates contraction of the uterine myometrium during labor and causes lactation. In addition to the characteristic architecture of GPCRs, members of the neurohypophysial peptide hormone receptor family share certain sequence motifs and exhibit related pharmacologies (5-7). The hormone binding site of these receptors includes residues in the TM bundle (8) and ECL1 (9) (10) (11) . It has also been reported that the N-terminus of the V 1a R and OTR are required for agonist binding (12, 13) . In particular, two charged residues (Arg 46 and Glu 54 ) in the V 1a R N-terminus are required for high affinity agonist binding but not antagonist binding (14, 15) . Likewise, Arg 34 in the N-terminus of the OTR is required for agonist binding (16) .
For GPCRs in general, the roles of extracellular residues are not well understood compared to residues in the TM domain. Nevertheless, extracellular residues are important for binding both amine (17) and peptide (18) ligands and have been implicated in ligand receptor-subtype specificity (19) , binding allosteric modulators (20) switching ligand agonist/antagonist properties (21) and human immunodeficiency virus co-receptor activity (22) . The aim of this study was to use the V 1a R to systematically investigate the function of extracellular charged residues which are highly conserved throughout a sub-family of peptide GPCRs. Using a combination of mutagenesis and molecular modelling, our results indicate that specific conserved charged residues in ECL1, ECL2 and ECL3 fulfil important roles in ligand binding, receptor activation, domain conformation and cell-surface expression. Mutant receptor constructs  Mutation of the V 1a R was made using a PCR approach as described previously (15 R  were  engineered  using  the  antisense  oligonucleotides: 5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GCG-GAA-GCG-GTA-GGT-GAT-GGC-CCA-GC-3', 5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GCG-GAA-GGC-GTA-GG-3',  5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GGC-GAA-GCG-G-3', 5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GGC-GGG-CCC-3' and 5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GGC-GCA-CAG-CCA-GTC-GGG-CCC- -GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC-GCG-GCA-CAG-CCA-GTC-GGG-CCC-GCG-GAA-GCG-GTA-GGT-GAT-CTC-CCA-GC-3', 5'-GGC-AAA-CAC-CTG-CAG-GTG-CTT-CAC-CAC- ATG-ACC-TCA-GGT-GTC-TTC-GTG-G-3'. This primer contained five base changes in the V 1a R sequence (shown in bold) that created the Ala mutation (shown in italics) unique silent Pfl23II and Eco81I restriction sites (for diagnostic purposes) and a KpnI restriction site (underlined) for subcloning into the V 1a R.
EXPERIMENTAL PROCEDURES

Materials
The [E332A]V 1a R mutation was made by PCR using both sense and antisense oligonucleotides. The sense primer was 5'-C-GAT-TCA-GCA-AAC-CCA-TCG-ATA-ACA-ATC-ACG-GCG-3'. This primer contained four base changes in the V 1a R sequence (indicated in bold) which created a unique functional ClaI restriction site (underlined) without altering the amino acid sequence and incorporated the Glu 332 →Ala mutation (shown in italics).
A KpnI/EcoRI digest of this PCR fragment was subcloned into the V 1a R.
The Radioligand binding assays  A washed cell membrane preparation of HEK 293T cells, transfected with the appropriate receptor construct, was prepared as previously described (23) presence (non-specific) or absence (total) of 1 µM LA. Plates were incubated for 90 min at 37 °C, before removal of the medium by aspiration. After three rinses with ice cold PBS, 0.5 ml of 0.1 M NaOH was added to each well to extract radioactivity. After 15 min incubation at 37 °C, the fluid from the plates was transferred to scintillation vials containing 10 ml HiSafe3 scintillant cocktail for counting. Cell-surface expression values were corrected for radioligand occupancy as described (26) using the radioligand affinity (K d ) experimentally determined for each construct.
Determination of cell-surface expression using ELISA  All receptor constructs incorporated an HA epitope tag in the N-terminus which enabled cell surface expression to be determined by ELISA (27) . Briefly, HEK 293T cells were seeded at a density of 1 x 10 5 cells/well in poly D-lysine-coated 12-well plates and transfected after 24 h using Transfast (Promega Corp., Southampton, UK). After 36 h, cells were fixed with 3.7 % (v/v) formaldehyde in TBS (20 mM TRIS, pH 7.5, 150 mM NaCl) for 15 min at 37 °C, then washed three times with TBS. Nonspecific binding was blocked with 1 % (w/v) BSA in TBS for 45 min. Anti-HA primary antibody (HA-7; Sigma, Poole, UK) was diluted to 1:1000 in TBS containing 1 % (w/v) BSA for 60 min at room temperature with occasional shaking, followed by three gentle washes with TBS. Cells were briefly re-blocked with 1 % (w/v) BSA in TBS for 15 min, prior to incubation with secondary antibody (alkaline phosphatase-conjugated goat anti-mouse;
Bio-Rad Laboratories, Hemel Hempstead, UK) diluted to 1:3000 in 1 % (w/v) BSA/TBS for 60 min with occasional shaking. Cells were washed three times with TBS before a colorimetric alkaline phosphate substrate (Bio-Rad Laboratories) was added and incubated at 37 °C for 30 min. A 100 µl aliquot from each well was mixed with an equal volume of 0.4 M NaOH prior to measuring absorbance at 405 nm. Results were normalized against a wild-type control processed in parallel. Non-transfected cells were used to determine background. All experiments were performed in quadruplet.
AVP-induced inositol phosphates
production  HEK 293T cells were seeded at a density of 2.5 x 10 5 cells/well in poly D-lysinecoated twelve well plates and transfected after 24 h using Transfast (Promega). AVP-induced accumulation of inositol phosphates (InsPs) was assayed as described previously (12) . Briefly, following pre-labeling of transfected cells with 2 µCi/ml myo- [2- 3 H]inositol (22.0 Ci/mmol; Perkin Elmer, Beaconsfield, UK) in inositol-free DMEM containing 1 % (v/v) FCS, a mixed fraction containing mono-, bis, and trisphosphates (InsPInsP 3 ) was collected following stimulation by AVP, at the concentrations indicated, in the presence of 10 mM LiCl.
Molecular modelling of the V 1a R  The V 1a R sequence was aligned against the sequence corresponding to the crystal structure coordinates of bRho using CLUSTALW (28) . The alignment was then used to generate homology models using MODELLER v6.2 (29). A collection of 200 model structures were generated and ranked based on an objective function score provided by MODELLER6v2. From this ensemble, a single structure was selected for further analysis. Further refinement of the homology model was achieved through molecular dynamics (MD) simulations of the receptor embedded in a hydrated 1,2-dipalmitoyl-sn-glycero-3-phosphocholine bilayer. MD simulations were carried out using the GROMOS96 force-field parameters, with minor modifications, as implemented in GROMACS (30) . Partial charges for the heavy atoms of Lys and Arg side-chains were determined using the 6-31G basis set as implemented in GAMESS US. (Fig. 1A) . Asp 112 is also conserved with the exception of the human V 2 R (Lys) and the VTR (Glu). Arg 118 is only conserved in V 1a Rs, although positively charged residues are present at this locus in all V 2 Rs (Fig. 1A) .
RESULTS
Role of charged residues
To assess the importance of these conserved residues in V 1a R function, each residue was substituted individually by Ala then pharmacologically characterized using the natural agonist AVP and three different structural classes of antagonist: (25) (Fig 2A) . In contrast, the binding affinities of the three different antagonists to [R116D]V 1a R, [R116E]V 1a R were relatively unchanged, although a small decrease (~6-fold) was observed for CA (Table I) . Incorporating a negative charge at this locus also perturbed receptor activation, increasing the EC 50 value for [R116D]V 1a R and [R116E]V 1a R by 53-fold and 23-fold respectively (Fig. 3A) . In contrast, maintaining a positive charge at this position ([R116K]V 1a R) resulted in a receptor which exhibited essentially wild-type binding ( Fig.  2A and Table I ) and signaling (Fig. 3A) .
A positive charge is required at residue-125 in ECL1  The charge requirements of residue-125 were investigated further. Retaining a positive charge ([R125K]V 1a R) resulted in a wildtype receptor profile (Table I ). In contrast, introduction of a negative charge at this locus ([R125D]V 1a R) ablated specific binding of the radio-tracers (agonist and antagonist) and impaired signaling, with a marked decrease in AVP potency compared to wild-type V 1a R (Fig. 3B ). Molecular modelling of the V 1a R indicated that Arg 125 orientates into the lipid bilayer (Fig. 4A) , with the side-chain methylene groups interacting with the lipid hydrocarbon tails and the guanidinium group interacting with the lipid phosphate head groups and solvent. These contacts are preserved in [R125K]V 1a R, consistent with the wild-type characteristics of this mutant receptor. In contrast, molecular dynamics of [R125D]V 1a R revealed a re-ordering of the phospholipids in this region resulting from mutual repulsion between the negatively-charged lipid phosphate head group and the carboxyl of the Asp side-chain. This reordering of the lipids increased solvent accessibility at the extracellular end of TMIII and TMIV (Fig. 4A) .
Species-specific and receptor subtypespecific differences at position-112 in ECL1  An
Asp is highly conserved at residue-112 throughout this family of GPCRs, with the exception of the VTR and the human V 2 R which possess Glu and Lys respectively (Fig. 1 ). Pharmacological differences arising from this sequence variation were assessed. Conservative substitution ([D112E]V 1a R) resulted in wild-type binding and intracellular signaling, with only a small change in affinity for the CA antagonist (3-fold). Reversing the charge in [D112K]V 1a R also slightly decreased the affinity of CA (5-fold) and reduced the affinity of the linear antagonist LA 8-fold (Table I) but was otherwise wild-type (Fig. 3C) . However, in marked contrast to [D112K]V 1a R, the construct [D112R]V 1a R exhibited low affinity for AVP (Fig.  2B ) and perturbed signaling (Fig. 3C) . These effects were not due to a non-specific disruption of the receptor tertiary fold as the affinity of the three classes of antagonist was unchanged (Table I) (Fig. 4B) . A comparable interaction between the amine of Lys 112 and Glu 54 is far less likely as the functional groups are further apart (4.8 Å). Furthermore, the guanidinium of Arg has higher partial charges on its heavy atoms compared to the amine of Lys, which increases the potential of the Arg guanidinium to establish ionic interactions compared to the amine of Lys. In addition, the planar nature of the guanidinium group may aid directive interactions.
Role (33) , (iii) a negative charge (usually a Glu but an Asp in V 2 Rs) is conserved at residue-195 with the exception of the human V 2 R which has Asn and (iv) a positive charge (Arg/Lys) is conserved at position-216 but is replaced by a Pro in the sheep V 1a R (Fig. 1A) .
To assess the functional importance of these conserved charged residues, each residue was mutated individually to Ala and the pharmacological characteristics compared to wildtype V 1a R (Table I) . With the exception of [D204A]V 1a R, all the mutant constructs exhibited binding and signaling characteristics similar to wild-type (Table I) . In marked contrast, [D204A]V 1a R possessed a marked decrease in AVP affinity (2300-fold; Fig. 2C and Table I ) and impaired signaling (Fig. 3D) . The affinity of [D204A]V 1a R for the cyclic and non-peptide antagonists remained unchanged (Table I) indicating that the receptor protein was folded appropriately, nevertheless the K d for LA was increased 20-fold relative to wild-type (Table I) Table I ), whereas reversing the charge ([D204R]V 1a R) markedly decreased both AVP affinity (Fig 2C) and signaling (Fig. 3D) and to a lesser extent LA and CA affinity (24-fold and 6-fold respectively; Table I (Table I) , and the signaling capability of [R46D/D204R]V 1a R was also severely compromised. The overall tertiary fold of the receptor was nevertheless good as the non-peptide antagonist bound with wild-type affinity and the peptide antagonists CA and LA also bound with high affinity, albeit less than wildtype (Table I) , both in TMIII (Fig. 4C ). These interactions with Lys 128(3.29) and Gln 131 (3.32) are preserved in the conservative substitution [D204E]V 1a R (not shown), consistent with the wild-type pharmacological profile (Table  I) . Removal of the negative charge at this locus ([D204A]V 1a R), resulted in a decrease in both AVP affinity and signaling potency (Fig. 3D , Table I ). MD simulation of [D204A]V 1a R revealed that removal of the negative charge breaks the wild-type contacts between ECL2 and TMIII (Fig.  4D) . This leads to a partial unfolding of thehairpin within ECL2 (Fig. 4E) . In addition, the side-chain of Lys 128 rotates away from its wildtype position and orientates towards TMVI (Fig.  4D) (Fig. 1B) . Analysis of sequence alignments of ECL3 of the vertebrate VPR/OTR family revealed that: (i) an Asp is completely conserved at the locus corresponding to Asp 323 , (ii) a negative charge (usually an Asp) is conserved at residue-330 in V 1a Rs, V 1b Rs and VTRs but is replaced by Pro in OTRs and V 2 Rs, (iii) a Glu is conserved at the locus corresponding to Glu 332 with the exception of V 1b Rs which possess a Thr (Fig. 1A) . To determine the functional importance of these residues, each residue was mutated individually to Ala. Pharmacological characterization established that
[D323A]V 1a R, [D330A]V 1a R and [E332A]V 1a R were almost identical to wild-type V 1a R with respect to binding all four classes of ligand (Table I ) and intracellular signalling ( Table  I ), indicating that the conserved charged residues in ECL3 had little or no role in these functions. It was however noteworthy that [D323A]V 1a R exhibited reduced cell-surface expression (c.50 %) compared to wild-type V 1a R (Table I) .
DISCUSSION
The aim of this study was to use the V 1a R to systematically investigate the function of extracellular charged residues which are highly conserved throughout a sub-family of peptide GPCRs. Within the ECL domains of the V 1a R, the charged residues were sub-divided into two groups (i) those that are conserved in all members of the sub-family and (ii) those that are conserved within a specific subtype. Thirteen conserved charged residues were identified in the ECL domains and associated TM boundaries, with five in ECL1, five in ECL2 and three in ECL3. Ala substitution within ECL1 had little effect on ligand binding. [R116E]V 1a R) not only compromised signaling but also profoundly decreased agonist affinity. This loss of AVP binding was agonist-specific and not due to aberrant assembly of the receptor as the binding of antagonists (peptide and non-peptide) was unaffected. Consequently, Arg 116 is required to stabilize the active R* conformation of the V 1a R and is absolutely conserved throughout the vertebrate neurohypophysial hormone sub-family of GPCRs cloned to-date (Fig. 1A) .
Arg 125 is located near to the extracellular end of TMIII, immediately adjacent to the conserved disulfide bond, where it interacts with lipids. This Arg-lipid interaction has been referred to as 'snorkeling' (35) . The absolute conservation of this Arg throughout the neurohypophysial peptide hormone receptor family (Fig. 1A) implies functional importance. This is supported by a report that the naturally-occurring mutation R113W in the human V 2 R (which corresponds to Arg 125 in the V 1a R) causes the receptor dysfunction responsible for nephrogenic diabetes insipidus (NDI) in some patients (36) . Furthermore, an alignment of 717 sequences of Family A GPCRs which bind peptide ligands, revealed that a positively charged residue is conserved at this position in 85 % of receptors and that Asp and Glu are excluded (GPCR database http://www.gpcr.org). This is indicative of a generic role for this residue in signaling by peptide-GPCRs, a notion supported by mutagenesis studies on the CXCR2 and angiotensin II type-1 receptors (37, 38) . It is now well-established that relative movement between TMIII, TMVI and TMVII is central to the R→R* transition of GPCRs (39) . The location of Arg 125 at the extracellular extremity of TMIII may allow it to act as a structural support for TMIII during receptor activation. Reversing the charge at this locus in [R125D]V 1a R was very detrimental due to charge-charge repulsion between the side-chain carboxyl and the membrane lipid phosphate headgroups. This repulsion resulted in re-ordering of the surrounding phospholipids, increased solvent accessibility at the extracellular end of TMIII/TMIV and altered local conformation which could have ramifications along the length of TMIII. These conformational changes observed in silico would explain why Asp/Glu are excluded from this locus in peptide-binding GPCRs. (41) . Asp 112 in the V 1a R is conserved throughout the neurohypophysial hormone receptor family with the exception of the human V 2 R and the VTR which possess Lys and Glu respectively. It has been reported that this locus is important for binding some V 2 R-selective agonists (42 ECL2 is usually the longest ECL in GPCRs and in bRho forms a -hairpin which projects into the binding crevice allowing the 4-strand to contact retinal (1, 2). There is also evidence that this ECL2 fold is not restricted to bRho and occurs in other GPCRs (43) . Of the five conserved charged residues substituted by Ala in ECL2 of the V 1a R, only [D204A]V 1a R had a marked effect on receptor function, with a profound decrease in AVP affinity, decreased LA affinity and impaired signaling potency. , Ser 273 (7.43) ) which reduced the R→R* transition. Interestingly, Ser 273(7.43) corresponds to the retinal attachment site in bRho and this locus has been implicated in activation of other GPCRs (44, 45) . In addition, Ala substitution of both of the TMII contacts, Gln 104(2.57) and Gln 108(2.61)
, has been reported previously to perturb both ligand binding and intracellular signaling (8) . Consequently, the inappropriate new contacts established by Arg 204 are with residues required for receptor activation and explain the perturbed pharmacological profile observed with [D204R]V 1a R. In contrast, the conservative substitution [D204E]V 1a R, which occurs naturally in a chick VTR (33) , maintains the normal ECL2-TMIII contacts and exhibits wildtype characteristics. Our investigations establish the importance of an acidic residue at position-204 and provide an explanation for the absolute conservation of Asp(Glu) at this locus throughout a sub-family of GPCRs. In addition, our study also provides a feasible mechanism for the naturallyoccurring 'loss-of-function' mutation D191G in the human V 2 R (corresponding to Asp 204 in the V 1a R) which has been identified as a cause of NDI in some families (46 
